Overview of Immunotherapy in Alzheimer's Disease (AD) and Mechanisms of IVIG Neuroprotection in Preclinical Models of AD

被引：16
|
作者：
Counts, Scott E. [1 ]
Lahiri, Debomoy K. [2 ]
机构：
[1] Michigan State Univ, Dept Family Med, Dep Translat Sci & Mol Med, Grand Rapids, MI 49503 USA
[2] Indiana Univ, Sch Med, Neurosci Res Ctr, Inst Psychiat Res,Dept Med & Mol Genet,Dept Psych, Indianapolis, IN 46202 USA
来源：
CURRENT ALZHEIMER RESEARCH | 2014年 / 11卷 / 07期
关键词：
AMYLOID-BETA-PEPTIDE; MOUSE MODEL; INTRAVENOUS IMMUNOGLOBULINS; TAU PATHOLOGY; IMMUNIZATION; ANTIBODY; BRAIN; PRESERVES; TOXICITY; TRIALS;
D O I：
10.2174/156720501107140815102453
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：623 / 625
页数：3
相关论文
共 50 条
  • [1] Disease progression modelling from preclinical Alzheimer’s disease (AD) to AD dementia
    Soo Hyun Cho
    Sookyoung Woo
    Changsoo Kim
    Hee Jin Kim
    Hyemin Jang
    Byeong C. Kim
    Si Eun Kim
    Seung Joo Kim
    Jun Pyo Kim
    Young Hee Jung
    Samuel Lockhart
    Rik Ossenkoppele
    Susan Landau
    Duk L. Na
    Michael Weiner
    Seonwoo Kim
    Sang Won Seo
    Scientific Reports, 11
  • [2] Disease progression modelling from preclinical Alzheimer's disease (AD) to AD dementia
    Cho, Soo Hyun
    Woo, Sookyoung
    Kim, Changsoo
    Kim, Hee Jin
    Jang, Hyemin
    Kim, Byeong C.
    Kim, Si Eun
    Kim, Seung Joo
    Kim, Jun Pyo
    Jung, Young Hee
    Lockhart, Samuel
    Ossenkoppele, Rik
    Landau, Susan
    Na, Duk L.
    Weiner, Michael
    Kim, Seonwoo
    Seo, Sang Won
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [3] PREVENTION OF ALZHEIMER DISEASE (AD): PLEIOTROPIC APPROACHES IN PRECLINICAL MODELS
    Cole, G.
    Frautschy, S.
    GERONTOLOGIST, 2011, 51 : 355 - 355
  • [4] TRAFFIC SIGN IDENTIFICATION AND DRIVING IN PRECLINICAL ALZHEIMER'S DISEASE (AD)
    Barco, P.
    Carr, D.
    Rutkoski, K. M.
    Wallendorf, M.
    Johnson, A.
    Vernon, K.
    Babulal, G. M.
    Roe, C. M.
    GERONTOLOGIST, 2015, 55 : 188 - 188
  • [5] Specific episodic memory deficits in a preclinical phase of Alzheimer's disease (AD)
    Elfgren, CI
    Gustafson, L
    Nilsson, LG
    Passant, U
    Rosén, I
    INTERNATIONAL JOURNAL OF PSYCHOLOGY, 2000, 35 (3-4) : 147 - 147
  • [6] Plasma sRAGE levels in Alzheimer's disease (AD) are increased by intravenous immunoglobulin (IVIg) treatment
    Lue, LF
    Smock, A
    Adamiak, B
    Monthe, C
    Szabo, P
    Schiff, R
    Weksler, ME
    Relkin, NR
    NEUROLOGY, 2006, 66 (05) : 284 - 285
  • [7] Statins in Alzheimer’s disease (AD)
    A. Vitiello
    V. Troiano
    R. La Porta
    European Journal of Clinical Pharmacology, 2022, 78 : 1201 - 1202
  • [8] Statins in Alzheimer's disease (AD)
    Vitiello, A.
    Troiano, V.
    La Porta, R.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (07) : 1201 - 1202
  • [9] Antroquinonol administration in animal preclinical studies for Alzheimer's disease (AD): A new avenue for modifying progression of AD pathophysiology
    Francesca, Fernandez
    Caitlin, Aust
    Sarah, Lye
    Robyn, Griffiths Lyn
    BRAIN BEHAVIOR & IMMUNITY-HEALTH, 2022, 21
  • [10] ALZHEIMER DISEASE: Aβ-independent processes-rethinking preclinical AD
    Chetelat, Gael
    NATURE REVIEWS NEUROLOGY, 2013, 9 (03) : 123 - 124
12345